|
1
|
Afifi AK: The landry-guillain-barré strohl
syndrome 1859 to 1992 a historical perspective. J Family Community
Med. 1:30–34. 1994.PubMed/NCBI
|
|
2
|
Dash S, Pai AR, Kamath U and Rao P:
Pathophysiology and diagnosis of guillain-barré syndrome-challenges
and needs. Int J Neurosci. 125:235–240. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hiraga A, Mori M, Ogawara K, Hattori T and
Kuwabara S: Differences in patterns of progression in demyelinating
and axonal guillain-barre syndromes. Neurology. 61:471–474.
2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Padmanabhan A, Connelly-Smith L, Aqui N,
Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu
Y, et al: Guidelines on the use of therapeutic apheresis in
clinical practice-evidence-based approach from the writing
committee of the american society for apheresis: The eighth special
issue. J Clin Apher. 34:171–354. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stoian A, Motataianu A, Bajko Z and Balasa
A: Guillain-Barré and acute transverse myelitis overlap syndrome
following obstetric surgery. J Crit Care Med (Targu Mures).
6:74–79. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Omejec G and Podnar S: Retrospective
analysis of slovenian patients with guillain-barré syndrome. J
Peripher Nerv Syst. 17:217–219. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kuwabara S: Axonal guillain-barré syndrome
is underestimated in Europe? J Neurol Neurosurg Psychiatry.
81(1063)2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kuwabara S and Yuki N: Axonal
guillain-barré syndrome: Concepts and controversies. Lancet Neurol.
12:1180–1188. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yuki N, Taki T, Inagaki F, Kasama T,
Takahashi M, Saito K, Handa S and Miyatake T: A bacterium
lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1
ganglioside-like structure. J Exp Med. 178:1771–1775.
1993.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ho TW, Willison HJ, Nachamkin I, Li CY,
Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, et al:
Anti-GD1a antibody is associated with axonal but not demyelinating
forms of guillain-barré syndrome. Ann Neurol. 45:168–173.
1999.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ang CW, Jacobs BC and Laman JD: The
guillain-barré syndrome: A true case of molecular mimicry. Trends
Immunol. 25:61–66. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kuwabara S, Bostock H, Ogawara K, Sung JY,
Kanai K, Mori M, Hattori T and Burke D: The refractory period of
transmission is impaired in axonal guillain-barré sindromes. Muscle
Nerve. 28:683–689. 2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hafer-Macko C, Hsieh ST, Li CY, Ho TW,
Sheikh K, Cornblath DR, McKhann GM, Asbury AK and Griffin JW: Acute
motor axonal neuropathy: An antibody-mediated attack on axolemma.
Ann Neurol. 40:635–644. 1996.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kalita J, Misra UK and Das M:
Neurophysiological criteria in the diagnosis of different clinical
types of guillain-barre syndrome. J Neurol Neurosurg Psychiatry.
79:289–293. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
van den Berg B, Walgaard C, Drenthen J,
Fokke C, Jacobs BC and van Doorn PA: Guillain-Barré syndrome:
Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol.
10:469–482. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hughes RA and Cornblath DR: Guillain-Barré
syndrome. Lancet. 366:1653–1666. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kuwabara S, Asahina M, Koga M, Mori M,
Yuki N and Hattori T: Two patterns of clinical recovery in
guillain-barré syndrome with IgG anti-GM1 antibody. Neurology.
51:1656–1660. 1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stoian A, Moțățăianu A, Bărcuțean L, Maier
S, Bazko Z, Voidăzan S, Fărcaș A and Bălașa R: Understandig the
mechanism of action of intravenous immunoglobulins: A ten years
experience in treating guillain-barré syndrome. Farmacia.
68:426–435. 2020.
|
|
19
|
Kleyweg RP, van der Meché FG and Schmitz
PI: Interobserver agreement in the assessment of muscle strength
and functional abilities in guillain-barré syndrome. Muscle Nerve.
14:1103–1109. 1991.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hughes RA, Newsom-Davis JM, Perkin GD and
Pierce JM: Controlled trial prednisolone in acute polyneuropathy.
Lancet. 2:750–753. 1978.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang G, Li Q, Zhang R, Wei X, Wang J and
Qin X: Subtypes and prognosis of guillain-barré syndrome in
Southwest China. PLoS One. 10(e0133520)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ho TW, Mishu B, Li CY, Gao CY, Cornblath
DR, Griffin JW, Asbury AK, Blaser MJ and McKhann GM: Guillain-Barre
syndrome in northern China Relationship to Campylobacter
jejuni infection and anti-glycolipid antibodies. Brain.
118:597–605. 1995.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ye Y, Wang K, Deng F and Xing Y:
Electrophysiological subtypes and prognosis of guillain-barré
syndrome in northeastern China. Muscle Nerve. 47:68–71.
2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Estrade S, Guiomard C, Fabry V, Baudou E,
Cances C, Chaix Y, Cintas P, Meyer P and Cheuret E: Prognostic
factors for the sequelae and severity of guillain-barré syndrome in
children. Muscle Nerve. 60:716–723. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hadden RD, Cornblath DR, Hughes RA,
Zielasek J, Hartung HP, Toyka KV and Swan AV: The plasma
exchange/sandoglobulin guillain-barré syndrome trial group.
electrophysiological classification of guillain-barré syndrome:
Clinical associations and outcome. Ann Neurol. 44:780–788.
1998.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Winer JB, Hughes RA, Anderson MJ, Jones
DM, Kangro H and Watkins RP: A prospective study of acute
idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg
Psychiatry. 51:613–618. 1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hemachudha T, Griffin DE, Chen WW and
Johnson RT: Immunologic studies of rabies vaccination-induced GBS.
Neurology. 38:375–378. 1998.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lasky T, Terracciano GJ, Magder L, Koski
CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD,
Schonberger LB and Chen RT: The guillain-barre´ syndrome and the
1992-1993 and 1993-1994 influenza vaccines. N Engl J Med.
339:1797–1802. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kozanoglu I, Yerdelen D, Buyukkurt N,
Yeral M, Boga C and Ozdogu H: A retrospective study on patients
with guillain-barré syndrome treated with therapeutic plasma
exchange and other treatment options-a centre's experience. Eur
Neurological Rev. 10:81–84. 2015.
|
|
30
|
Huy PP and Schwartz J: Therapeutic plasma
exchange in guillain-barré syndrome and chronic inflammatory
demyelinating polyradiculoneuropathy. Presse Med. 48:338–346.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chevret S, Hughes RA and Annane D: Plasma
exchange for guillain-barré syndrome. Cochrane Database Syst Rev.
2(CD00179)2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
McKhann GM, Griffin JW, Cornblath DR,
Mellits ED, Fisher RS and Quaskey SA: Plasmapheresis and
guillain-barré syndrome: Analysis of prognostic factors and the
effect of plasmapheresis. Ann Neurol. 23:347–353. 1998.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Derksen RH, Schuurman HJ, Meyling FH,
Struyvenberg A and Kater L: The efficacy of plasma exchange in the
removal of plasma components. J Lab Clin Med. 104:346–354.
1984.PubMed/NCBI
|
|
34
|
Appropriate number of plasma exchanges in
Guillain-Barré syndrome. The French Cooperative Group on plasma
exchange in Guillain-Barré syndrome. Appropriate number of plasma
exchanges in Guillain-Barré syndrome. Ann Neurol. 41:298–306.
1997.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Espérou H, Jars-Guincestre MC, Bolgert F,
Raphaël JC and Durand-Zaleski I: French cooperative group on plasma
exchange in guillain-barré syndrome. Cost-effectiveness of plasma
exchange therapy for the treatment of guillain-barré syndrome.
Intensive Care Med. 26:1094–1100. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shemin D, Briggs D and Greenan M:
Complications of therapeutic plasma exchange: A prospective study
of 1,727 procedures. J Clin Apher. 22:270–276. 2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Dhanya NB, Rai R and Srinivas CR:
Histamine 2 blocker potentiates the effects of histamine 1 blocker
in suppressing histamine-induced wheal. Indian J Dermatol Venereol
Leprol. 74:475–477. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ogawara K, Kuwabara S, Mori M, Hattori T,
Koga M and Yuki N: Axonal guillain-barré syndrome: Relation to
anti-ganglioside antibodies and Campylobacter jejuni
infection in Japan. Ann Neurol. 48:624–631. 2000.PubMed/NCBI
|
|
39
|
Paradiso G, Tripoli J, Galicchio S and
Fejerman N: Epidemiological, clinical, and electrodiagnostic
findings in childhood guillain-barré syndrome: A reappraisal. Ann
Neurol. 46:701–717. 1999.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Chareyre J, Hully M, Simonnet H, Musset L,
Barnerias C, Kossorotoff M, Quijano-Roy S, Desguerre I and Gitiaux
C: Acute axonal neuropathy subtype of guillain barré syndrome in a
French pediatric series: Adequate follow-up may require repetitive
electrophysiological studies. Eur J Paediatr Neurol. 21:891–897.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tekgul H, Serdaroglu G and Tutuncuoglu S:
Outcome of axonal and demyelinating forms of guillain-barré
syndrome in children. Pediatr Neurol. 28:295–299. 2003.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang Y, Zhao Y and Wang Y: Prognostic
factors of guillain-barré syndrome: A 111-case retrospective
review. Chin Neurosurg J. 14:1–9. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Akbayram S, Doğan M, Akgün C, Peker E,
Sayιn R, Aktar F, Bektaş MS and Caksen H: Clinical features and
prognosis with guillain-barré syndrome. Ann Indian Acad Neurol.
14:98–102. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gonzalez-Suarez I, Sanz-Gallego I,
Rodriguez de Rivera FJ and Arpa J: Guillain-Barre syndrome: Natural
history and prognostic factors: A retrospective review of 106
cases. BMC Neurol. 13(95)2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bradshaw DY and Jones HR Jr:
Guillain-Barré syndrome in children: Clinical course,
electrodiagnosis, and prognosis. Muscle Nerve. 15:500–506.
1992.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Raphaël JC, Chevret S, Hughes RA and
Annane D: Plasma exchange for guillain-barré syndrome. Cochrane
Database Syst Rev. 7(CD001798)2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Walgaard C, Lingsma HF, Ruts L, van Doorn
PA, Steyerberg EW and Jacobs BC: Early recognition of poor
prognosis in guillain-barre syndrome. Neurology. 76:968–975.
2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lee JH, Sung IY and Rew IS: Clinical
presentation and prognosis of childhood guillain-barré syndrome. J
Paediatr Child Health. 44:449–454. 2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sakakibara R, Hattori T, Kuwabara S,
Yamanishi T and Yasuda K: Micturitional disturbance in patients
with guillain-barre syndrome. J Neurol Neurosurg Psychiatr.
63:649–653. 1997.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sharshar T, Chevret S, Bourdain F and
Raphaël JC: French cooperative group on plasma exchange in
guillain-barré syndrome. Early predictors of mechanical ventilation
in guillain-barré syndrome. Crit Care Med. 31:278–283.
2003.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Van Doorn PA, Ruts L and Jacobs BC:
Clinical features, pathogenesis, and treatment of guillain-barré
syndrome. Lancet Neurol. 7:939–950. 2008.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Van Doorn PA, Kuitwaard K, Walgaard C, van
Koningsveld R, Ruts L and Jacobs BC: IVIG treatment and prognosis
in guillain-barré syndrome. J Clin Immunol. 30 (Suppl):S74–S78.
2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Buzzigoli SB, Genovesi M, Lambelet P, Logi
C, Raffaelli S and Cattano D: Plasmapheresis treatment in
guillain-barré syndrome: Potential benefit over intravenous
immunoglobulin. Anaesth Intensive Care. 38:387–389. 2010.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Dada MA and Kaplan AA: Plasmapheresis
treatment in guillain-barré syndrome: Potential benefit over IVIg
in patients with axonal involvement. Ther Apher Dial. 8:409–412.
2004.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chaudhuri JR, Alladi S, Mridula KR, Boddu
DB, Rao MV, Hemanth C, Dhanalaxmi V, Reddy JM, Rao SM, Balaraju B,
et al: Clinical outcome of Guillain-Barré syndrome with various
treatment methods and cost effectiveness: A study from tertiary
care center in South India: Yashoda GBS Registry. Neurol Asia.
19:263–270. 2014.
|
|
56
|
Nagpal S, Benstead T, Shumak K, Rock G,
Brown M and Anderson DR: Treatment of guillain-barré syndrome: A
cost-effectiveness analysis. J Clin Apher. 14:107–113.
1999.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Winters JL, Brown D, Hazard E, Chainani A
and Andrzejewski C Jr: Cost-Minimization analysis of the direct
costs of TPE and IVIg in the treatment of guillain-barré syndrome.
BMC Health Serv Res. 11(101)2011.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Balasa R: Therapeutic plasma exchange: An
indispensable therapy for severe neurological condition. J Crit
Care Med (Targu Mures). 6:89–90. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Al Hamdani S, Aljanabi FY, Abdulrasool MI
and Salman AH: Child with guillain-barré syndrome responding to
plasmapheresis: A case report. Case Rep Acute Med. 3:4–11.
2020.PubMed/NCBI View Article : Google Scholar
|
